Investors Alert : Violin Memory, Inc. (NYSE:VMEM), Wright Medical Group Inc. (NASDAQ:WMGI), Nationstar Mortgage Holdings Inc. (NYSE:NSM), Halozyme Therapeutics, Inc. (NASDAQ:HALO), AT&T, Inc. (NYSE:T)

Violin Memory (NASDAQ:VMEM) has earned an average recommendation of “Hold” from the eight analysts that are covering the company, Analyst Ratings.Net reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a buy recommendation to the company. Violin Memory, Inc. (NYSE:VMEM) belongs to Technology sector. Its weekly performance is 6.82%. On last trading day company shares ended up $4.70. Violin Memory, Inc. (NYSE:VMEM) distance from 50-day simple moving average (SMA50) is 8.12%.

Wright Medical Group Inc. (NASDAQ:WMGI). is on the grow again. The Memphis-based company is merging with Netherlands-based Tornier N.V., an orthopedic extremities manufacturer, a deal worth an estimated $3.3 billion. Wright Medical Group Inc. (NASDAQ:WMGI) shares moved down -0.95% in last trading session and ended the day at $31.34. WMGI Gross Margin is 74.40% and its return on assets is -34.40%. Wright Medical Group Inc. (NASDAQ:WMGI) quarterly performance is -0.35%.

On October 23, Nationstar Mortgage Holdings Inc. (NYSE:NSM) announced that it will report third quarter 2014 financial results and will discuss Nationstar’s business outlook on Thursday, November 6, 2014. Nationstar invites all interested persons to participate on its conference call at 9:00 a.m., Eastern Time. On 28 October, Nationstar Mortgage Holdings Inc. (NYSE:NSM) shares increased 2.72% and was closed at $34.35. NSM EPS growth in last 5 year was 27.10%. Nationstar Mortgage Holdings Inc. (NYSE:NSM) year to date (YTD) performance is -7.06%.

On Oct. 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex®recombinant (hyaluronidase human injection). The FDA approved the use of the Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, the active ingredient used in Hylenex, and the Patheon® facility in Greenville, North Carolina, for production of finished Hylenex product. Halozyme Therapeutics, Inc. (NASDAQ:HALO) ended the last trading day at $9.36. Company weekly volatility is calculated as 4.04% and price to cash ratio as 7.95. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a weekly performance of 2.63%.

The Federal Trade Commission said Tuesday it is suing AT&T, Inc. (NYSE:T)for promising unlimited data plans to customers and then slowing Internet speeds during their browsing. AT&T, Inc. (NYSE:T) belongs to Technology sector. Its net profit margin is 13.00% and weekly performance is -0.84%. On last trading day company shares ended up $34.33. AT&T, Inc. (NYSE:T) distance from 50-day simple moving average (SMA50) is -0.22%.